Analyzing the Role of Cyfip2 in the Mouse Brain

Total Page:16

File Type:pdf, Size:1020Kb

Analyzing the Role of Cyfip2 in the Mouse Brain Analyzing the Role of CyFIP2 in the Mouse Brain Dissertation zur Erlangung des Doktorgrades (Dr. rer. nat.) der Mathematisch-Naturwissenschaftlichen Fakultät der Rheinischen Friedrich-Wilhelms Universität Bonn Vorgelegt von Ö Ilkin Deniz zer aus Trabzon, Türkei Bonn, 2020 Angefertigt mit Genehmigung der Mathematischen-Naturwissenschaftlichen-Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn. 1. Gutachter: Prof. Dr. rer. nat. Walter Witke 2. Gutachter: Prof. Dr. rer. nat. Frank Bradke Tag der Promotion: 05.06.2020 Erscheinungsjahr: 2020 To my parents, for making everything possible. Summary An important regulator of neuron outgrowth, growth cone motility and dendritic spine formation is the actin nucleator ARP2/3, a protein complex that functions in forming branched actin networks. ARP2/3 complex activity is regulated by the class I nucleation promoting factor WAVE regulatory complex (WRC). In the brain, a crucial component of the pentameric WRC is the Cytoplasmic Fragile-X Mental Retardation Protein (FMRP) Interacting Protein 2 (CyFIP2) that is highly expressed in neurons. Knockout of the Cyfip2 gene in mice leads to perinatal lethality. When Cyfip2 is conditionally knocked out exclusively in the central nervous system (CNS), the mice fully recapitulate the complete knockout phenotype, thus suggesting a specific role for CyFIP2 in the CNS. Here we present our studies on a viable Cyfip2 conditional knockout mouse model, in which the deletion of the gene occurs at around postnatal day 18 (P18) mainly in hippocampal and cortical glutamatergic neurons. Upon complete loss of CyFIP2, we observed an increase of the small, dynamic actin filaments with no detectable changes in the stable actin pool. The analysis of excitatory synaptic transmission using patch-clamp recordings as well as Schaffer collateral stimulation recordings showed decreased excitatory synaptic transmission and defects in pre-synaptic vesicle exocytosis in the hippocampus. Using electron microscopy, we also showed reduced pre-synaptic bouton area accompanied by decreased neurotransmitter vesicle density in both Schaffer collaterals and mossy fibers, while post-synaptic densities did not appear significantly altered. In aged mice lacking CyFIP2, we observed increased dendritic spine number possibly in an attempt to compensate for the defects observed in the pre-synapse. These spines were mostly immature, phenocopying the Fragile-X syndrome mouse model. Lastly, a combination of behavioral tests showed a mild anxiety-like phenotype in Cyfip2 forebrain knockout mice with no defects in working and short-term memory according to Y-maze and novel object recognition experiments, respectively. Our electrophysiological, morphological and biochemical results together suggest a role of CyFIP2 in the structural maintenance of pre-synaptic terminals and dendritic spine maturation in the adult mouse brain that does not appear to be relevant for neurodegenerative processes, but rather for intellectual disability. iv Table of Contents List of Figures ............................................................................................................. x List of Tables ........................................................................................................... xiii Abbreviations ........................................................................................................... xiv 1. INTRODUCTION ................................................................................................... 1 1.1 The actin cytoskeleton ......................................................................................... 2 1.1.1. Actin binding proteins ................................................................................... 3 1.1.2. Actin nucleation factors ................................................................................ 4 1.1.3. The WAVE regulatory complex .................................................................... 6 1.1.4. The CyFIP1 isoform ..................................................................................... 7 1.1.5. The CyFIP2 isoform ..................................................................................... 9 1.1.5.1. CyFIP2 is expressed predominantly in brain........................................ 10 1.1.5.2. Alzheimer’s-like phenotype of Cyfip2+/- mice ....................................... 10 1.2. The nervous system .......................................................................................... 11 1.2.1. The synapse ............................................................................................... 12 1.2.2. Synaptic transmission ................................................................................ 13 1.2.3. Actin in the synapse ................................................................................... 16 1.2.3.1. Actin in synaptogenesis ....................................................................... 16 1.2.3.2. Actin in pre-synaptic boutons ............................................................... 17 1.2.3.3. Actin in dendritic spines ....................................................................... 18 1.3. Dementia .......................................................................................................... 19 1.3.1. Alzheimer’s disease ................................................................................... 20 1.3.1.1. APP processing ................................................................................... 21 1.3.1.2. Mouse models for Alzheimer’s disease ............................................... 22 1.3.2. Behavioral paradigms ................................................................................. 23 1.4. The Cyfip2flx/flx;Camk2a-Cre mouse model ....................................................... 25 1.5. Aim of the thesis ............................................................................................... 26 v 2. RESULTS ............................................................................................................ 27 2.1. CyFIP2 expression in the mouse brain ............................................................. 28 2.1.1. Glutamatergic neurons express CyFIP2 ..................................................... 28 2.1.2. Glial cells are devoid of CyFIP2 ................................................................. 30 2.2. Analysis of Cyfip2 conditional knockout mice ................................................... 31 2.2.1. CyFIP2 has a long half-life in vivo .............................................................. 32 2.2.2. WRC components are co-regulated with CyFIP2 ....................................... 33 2.2.3. CyFIP2 loss leads to an increase of small actin filaments .......................... 34 2.3. Synaptic analysis of Cyfip2 conditional knockout mice ..................................... 36 2.3.1. CyFIP2 loss leads to defects in synaptic transmission ............................... 36 2.3.2. Cyfip2 conditional knockout mice have decreased pre-synaptic vesicle exocytosis ............................................................................................................ 38 2.3.3. Loss of CyFIP2 leads to pre-synaptic terminal shrinkage in the hippocampus ............................................................................................................................. 41 2.3.4. CyFIP2 loss leads to altered levels of certain pre-synaptic proteins upon aging .................................................................................................................... 43 2.4. Evaluation of an Alzheimer’s-like phenotype in Cyfip2 conditional knockout mice ................................................................................................................................. 44 2.4.1. Cyfip2 conditional knockout mice show some molecular signatures of Alzheimer’s disease ............................................................................................. 45 2.4.2. CyFIP2 is involved in mRNA translation regulation .................................... 48 2.5. Morphological analysis of Cyfip2 conditional knockout mice reveals a phenotype similar to Fragile-X Syndrome .................................................................................. 49 2.5.1. Cyfip2 conditional knockout mice have increased number of spines .......... 49 2.5.2. CyFIP2 loss leads to decreased mature/immature spine ratios.................. 51 2.6. Behavioral analysis of Cyfip2 conditional knockout mice .................................. 54 2.6.1. Cyfip2 conditional knockout mice show decreased exploratory behavior ... 54 2.6.2. Cyfip2 conditional knockout mice have unaltered working memory ........... 57 2.6.3. CyFIP2 loss does not affect object recognition memory ............................. 59 vi 3. DISCUSSION ...................................................................................................... 61 3.1. CyFIP2 is expressed in glutamatergic and cholinergic neurons but not in glia cells.......................................................................................................................... 62 3.2. CyFIP2 is crucial for WRC integrity and regulation of dynamic actin filaments . 63 3.3. Cyfip2 conditional knockout mice show molecular and morphological signs of neurodegeneration with no memory defects ............................................................ 66 3.4. CyFIP2 loss leads to an FXS-like phenotype in the post-synapse .................... 68 3.5.
Recommended publications
  • S41436-020-01011-X.Pdf
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2020 New insights into the clinical and molecular spectrum of the novel CYFIP2-related neurodevelopmental disorder and impairment of the WRC-mediated actin dynamics Begemann, Anaïs ; Sticht, Heinrich ; Begtrup, Amber ; Vitobello, Antonio ; Faivre, Laurence ; Asadollahi, Reza ; Zweier, Markus ; Steindl, Katharina ; Rauch, Anita Abstract: PURPOSE A few de novo missense variants in the cytoplasmic FMRP-interacting protein 2 (CYFIP2) gene have recently been described as a novel cause of severe intellectual disability, seizures, and hypotonia in 18 individuals, with p.Arg87 substitutions in the majority. METHODS We assembled data from 19 newly identified and all 18 previously published individuals with CYFIP2 variants. By structural modeling and investigation of WAVE-regulatory complex (WRC)-mediated actin polymerization in six patient fibroblast lines we assessed the impact of CYFIP2 variants on the WRC. RESULTS Sixteenof 19 individuals harbor two previously described and 11 novel (likely) disease-associated missense variants. We report p.Asp724 as second mutational hotspot (4/19 cases). Genotype-phenotype correlation con- firms a consistently severe phenotype in p.Arg87 patients but a more variable phenotype inp.Asp724 and other substitutions. Three individuals with milder phenotypes carry putative loss-of-function vari- ants, which remain of unclear pathogenicity. Structural modeling predicted missense variants to disturb interactions within the WRC or impair CYFIP2 stability. Consistent with its role in WRC-mediated actin polymerization we substantiate aberrant regulation of the actin cytoskeleton in patient fibroblasts. CONCLUSION Our study expands the clinical and molecular spectrum of CYFIP2-related neurodevel- opmental disorder and provides evidence for aberrant WRC-mediated actin dynamics as contributing cellular pathomechanism.
    [Show full text]
  • Supplemental Information
    Supplemental information Dissection of the genomic structure of the miR-183/96/182 gene. Previously, we showed that the miR-183/96/182 cluster is an intergenic miRNA cluster, located in a ~60-kb interval between the genes encoding nuclear respiratory factor-1 (Nrf1) and ubiquitin-conjugating enzyme E2H (Ube2h) on mouse chr6qA3.3 (1). To start to uncover the genomic structure of the miR- 183/96/182 gene, we first studied genomic features around miR-183/96/182 in the UCSC genome browser (http://genome.UCSC.edu/), and identified two CpG islands 3.4-6.5 kb 5’ of pre-miR-183, the most 5’ miRNA of the cluster (Fig. 1A; Fig. S1 and Seq. S1). A cDNA clone, AK044220, located at 3.2-4.6 kb 5’ to pre-miR-183, encompasses the second CpG island (Fig. 1A; Fig. S1). We hypothesized that this cDNA clone was derived from 5’ exon(s) of the primary transcript of the miR-183/96/182 gene, as CpG islands are often associated with promoters (2). Supporting this hypothesis, multiple expressed sequences detected by gene-trap clones, including clone D016D06 (3, 4), were co-localized with the cDNA clone AK044220 (Fig. 1A; Fig. S1). Clone D016D06, deposited by the German GeneTrap Consortium (GGTC) (http://tikus.gsf.de) (3, 4), was derived from insertion of a retroviral construct, rFlpROSAβgeo in 129S2 ES cells (Fig. 1A and C). The rFlpROSAβgeo construct carries a promoterless reporter gene, the β−geo cassette - an in-frame fusion of the β-galactosidase and neomycin resistance (Neor) gene (5), with a splicing acceptor (SA) immediately upstream, and a polyA signal downstream of the β−geo cassette (Fig.
    [Show full text]
  • A-To-I RNA Editing Does Not Change with Age in the Healthy Male Rat Brain
    Biogerontology (2013) 14:395–400 DOI 10.1007/s10522-013-9433-8 RESEARCH ARTICLE A-to-I RNA editing does not change with age in the healthy male rat brain Andrew P. Holmes • Shona H. Wood • Brian J. Merry • Joa˜o Pedro de Magalha˜es Received: 18 January 2013 / Accepted: 15 May 2013 / Published online: 26 May 2013 Ó The Author(s) 2013. This article is published with open access at Springerlink.com Abstract RNA editing is a post-transcriptional pro- Introduction cess, which results in base substitution modifications to RNA. It is an important process in generating Adenosine to inosine (A-to-I) RNA editing is a post- protein diversity through amino acid substitution and transcriptional process that alters the sequences of the modulation of splicing events. Previous studies RNA molecules. The adenosine deaminases ADAR have suggested a link between gene-specific reduc- and ADARB1 convert specific adenosine residues on tions in adenosine to inosine RNA editing and aging in RNA to inosine bases. During translation, sequencing, the human brain. Here we demonstrate that changes in and splicing, inosine is recognized as guanosine. RNA editing observed in humans with age are not Therefore, A-to-I RNA editing has important impli- observed during aging in healthy rats. Furthermore, we cations in altering specific amino acids, miRNA identify a conserved editing site in rats, in Cog3.We targeting, and in the modulation of alternative splicing propose that either age-related changes in RNA (Nishikura 2010). editing are specific to primates or humans, or that Targets of A-to-I RNA editing are often genes they are the manifestation of disease pathology.
    [Show full text]
  • Spatially Clustering De Novo Variants in CYFIP2, Encoding the Cytoplasmic FMRP Interacting Protein 2, Cause Intellectual Disability and Seizures
    European Journal of Human Genetics (2019) 27:747–759 https://doi.org/10.1038/s41431-018-0331-z ARTICLE Spatially clustering de novo variants in CYFIP2, encoding the cytoplasmic FMRP interacting protein 2, cause intellectual disability and seizures 1 1,2 3 3 2,4 5,6 Markus Zweier ● Anaïs Begemann ● Kirsty McWalter ● Megan T. Cho ● Lucia Abela ● Siddharth Banka ● 7 8 9,10 11 12 Bettina Behring ● Andrea Berger ● Chester W. Brown ● Maryline Carneiro ● Jiani Chen ● 13 14 13 Gregory M. Cooper ● Deciphering Developmental Disorders (DDD) Study ● Candice R. Finnila ● 3 15 16 1 5,6 17,18 Maria J. Guillen Sacoto ● Alex Henderson ● Ulrike Hüffmeier ● Pascal Joset ● Bronwyn Kerr ● Gaetan Lesca ● 19 5 20 3 9 Gloria S. Leszinski ● John Henry McDermott ● Meira R. Meltzer ● Kristin G. Monaghan ● Roya Mostafavi ● 21,22 2,4,23 24 12 21,22,25 Katrin Õunap ● Barbara Plecko ● Zöe Powis ● Gabriela Purcarin ● Tiia Reimand ● 19,26 20 27 12,28 29 Korbinian M. Riedhammer ● John M. Schreiber ● Deepa Sirsi ● Klaas J. Wierenga ● Monica H. Wojcik ● 1,30 1 31 1,2,32,33 Sorina M. Papuc ● Katharina Steindl ● Heinrich Sticht ● Anita Rauch Received: 30 May 2018 / Revised: 31 October 2018 / Accepted: 7 November 2018 / Published online: 21 January 2019 © European Society of Human Genetics 2019 1234567890();,: 1234567890();,: Abstract CYFIP2, encoding the evolutionary highly conserved cytoplasmic FMRP interacting protein 2, has previously been proposed as a candidate gene for intellectual disability and autism because of its important role linking FMRP-dependent transcription regulation and actin polymerization via the WAVE regulatory complex (WRC). Recently, de novo variants affecting the amino acid p.Arg87 of CYFIP2 were reported in four individuals with epileptic encephalopathy.
    [Show full text]
  • Comparative RNA Editing in Autistic and Neurotypical Cerebella
    Molecular Psychiatry (2013) 18, 1041–1048 & 2013 Macmillan Publishers Limited All rights reserved 1359-4184/13 www.nature.com/mp ORIGINAL ARTICLE Comparative RNA editing in autistic and neurotypical cerebella A Eran1,2,JBLi3, K Vatalaro2, J McCarthy2, F Rahimov2,4, C Collins2,4, K Markianos2,5, DM Margulies5,6,7, EN Brown1,8,9, SE Calvo10, IS Kohane1,5,7 and LM Kunkel2,4,5,11 Adenosine-to-inosine (A-to-I) RNA editing is a neurodevelopmentally regulated epigenetic modification shown to modulate complex behavior in animals. Little is known about human A-to-I editing, but it is thought to constitute one of many molecular mechanisms connecting environmental stimuli and behavioral outputs. Thus, comprehensive exploration of A-to-I RNA editing in human brains may shed light on gene–environment interactions underlying complex behavior in health and disease. Synaptic function is a main target of A-to-I editing, which can selectively recode key amino acids in synaptic genes, directly altering synaptic strength and duration in response to environmental signals. Here, we performed a high-resolution survey of synaptic A-to-I RNA editing in a human population, and examined how it varies in autism, a neurodevelopmental disorder in which synaptic abnormalities are a common finding. Using ultra-deep (41000 Â ) sequencing, we quantified the levels of A-to-I editing of 10 synaptic genes in postmortem cerebella from 14 neurotypical and 11 autistic individuals. A high dynamic range of editing levels was detected across individuals and editing sites, from 99.6% to below detection limits. In most sites, the extreme ends of the population editing distributions were individuals with autism.
    [Show full text]
  • Altered Adenosine-To-Inosine RNA Editing in Human Cancer
    Downloaded from genome.cshlp.org on September 26, 2021 - Published by Cold Spring Harbor Laboratory Press Letter Altered adenosine-to-inosine RNA editing in human cancer Nurit Paz,1,2 Erez Y. Levanon,3,12 Ninette Amariglio,1,2 Amy B. Heimberger,4 Zvi Ram,5 Shlomi Constantini,6 Zohar S. Barbash,1,2 Konstantin Adamsky,1 Michal Safran,1,2 Avi Hirschberg,1,2 Meir Krupsky,2,7 Issachar Ben-Dov,2,8 Simona Cazacu,9 Tom Mikkelsen,9 Chaya Brodie,9,10 Eli Eisenberg,11 and Gideon Rechavi1,2,13 1Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel; 2Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel; 3Compugen Ltd., Tel Aviv 69512, Israel; 4Department of Neurosurgery, Brain Tumor Center, University of Texas M.D. Anderson Cancer Center, Houston 77030, Texas, USA; 5Department of Neurosurgery, Sourasky Medical Center, Tel Aviv 64239, Israel; 6Department of Pediatric Neurosurgery, Dana Children’s Hospital, Sourasky Medical Center, Tel Aviv 64239, Israel; 7Department of Internal Medicine, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel; 8Pulmonary Institute, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel; 9Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, Michigan 48202, USA; 10Neuro-Oncology Branch, NCI/NINDS, NIH, Bethesda 20892, Maryland, USA; 11School of Physics and Astronomy, Raymond and Beverly Sackler Faculty of Exact Sciences, Tel Aviv University 69978 Israel Adenosine-to-inosine (A-to-I) RNA editing was recently shown to be abundant in the human transcriptome, affecting thousands of genes. Employing a bioinformatic approach, we identified significant global hypoediting of Alu repetitive elements in brain, prostate, lung, kidney, and testis tumors.
    [Show full text]
  • BMC Genomics Biomed Central
    BMC Genomics BioMed Central Research article Open Access Genomic analysis of the chromosome 15q11-q13 Prader-Willi syndrome region and characterization of transcripts for GOLGA8E and WHCD1L1 from the proximal breakpoint region Yong-hui Jiang*1, Kekio Wauki1,3, Qian Liu1, Jan Bressler1, Yanzhen Pan1, Catherine D Kashork1,2, Lisa G Shaffer1,2 and Arthur L Beaudet1 Address: 1Departments of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA, 2Signature Genomics Laboratories, LLC, 120 North Pine Street, Suite 242C, Spokane, WA 99202, USA and 3Shinshu University School of Medicine, Dept of Medical Genetics, 3-1-1 Asahi, Nagano, Matsumoto 390-8621, Japan Email: Yong-hui Jiang* - [email protected]; Kekio Wauki - [email protected]; Qian Liu - [email protected]; Jan Bressler - [email protected]; Yanzhen Pan - [email protected]; Catherine D Kashork - [email protected]; Lisa G Shaffer - [email protected]; Arthur L Beaudet - [email protected] * Corresponding author Published: 28 January 2008 Received: 20 September 2007 Accepted: 28 January 2008 BMC Genomics 2008, 9:50 doi:10.1186/1471-2164-9-50 This article is available from: http://www.biomedcentral.com/1471-2164/9/50 © 2008 Jiang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Prader-Willi syndrome (PWS) is a neurobehavioral disorder characterized by neonatal hypotonia, childhood obesity, dysmorphic features, hypogonadism, mental retardation, and behavioral problems.
    [Show full text]
  • Evolutionarily Conserved Human Targets of Adenosine to Inosine RNA Editing Erez Y
    1162–1168 Nucleic Acids Research, 2005, Vol. 33, No. 4 doi:10.1093/nar/gki239 Evolutionarily conserved human targets of adenosine to inosine RNA editing Erez Y. Levanon1,2,*, Martina Hallegger3, Yaron Kinar1, Ronen Shemesh1, Kristina Djinovic-Carugo4, Gideon Rechavi2, Michael F. Jantsch3 and Eli Eisenberg1,5 1Compugen Ltd, 72 Pinchas Rosen St, Tel-Aviv 69512, Israel, 2Department of Pediatric Hemato-Oncology, Safra Children’s Hospital, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, 3Max F. Perutz Laboratories, Department of Chromosome Biology, University of Vienna, Rennweg 14, A-1030 Vienna, Austria, 4Max F. Perutz Laboratories, University Departments at Vienna Biocenter, Institute for Theoretical Chemistry and Molecular Structural Biology, University of Vienna, Campus Vienna Biocenter 6/1, Rennweg 95b, A-1030 Vienna, Austria and 5School of Physics and Astronomy, Raymond and Beverly Sackler Faculty of Exact Sciences, Tel Aviv University, Tel Aviv 69978, Israel Received December 23, 2004; Accepted January 20, 2005 ABSTRACT the double-stranded RNA-specific ADAR family predomin- antly acting on precursor messenger RNAs (2). As inosines in A-to-I RNA editing by ADARs is a post-transcriptional mRNA are recognized as guanosines (G) by the ribosome in mechanism for expanding the proteomic repertoire. the course of translation, RNA-editing can lead to the forma- Genetic recoding by editing was so far observed for tion of an altered protein if editing leads to a codon exchange. only a few mammalian RNAs that are predominantly ADAR-mediated RNA editing is essential for the development expressed in nervous tissues. However, as these edit- and normal life of both invertebrates and vertebrates (3–5).
    [Show full text]
  • A-To-I RNA Editing Does Not Change with Age in the Healthy Male Rat Brain
    Biogerontology DOI 10.1007/s10522-013-9433-8 RESEARCH ARTICLE A-to-I RNA editing does not change with age in the healthy male rat brain Andrew P. Holmes • Shona H. Wood • Brian J. Merry • Joa˜o Pedro de Magalha˜es Received: 18 January 2013 / Accepted: 15 May 2013 Ó The Author(s) 2013. This article is published with open access at Springerlink.com Abstract RNA editing is a post-transcriptional pro- Introduction cess, which results in base substitution modifications to RNA. It is an important process in generating Adenosine to inosine (A-to-I) RNA editing is a post- protein diversity through amino acid substitution and transcriptional process that alters the sequences of the modulation of splicing events. Previous studies RNA molecules. The adenosine deaminases ADAR have suggested a link between gene-specific reduc- and ADARB1 convert specific adenosine residues on tions in adenosine to inosine RNA editing and aging in RNA to inosine bases. During translation, sequencing, the human brain. Here we demonstrate that changes in and splicing, inosine is recognized as guanosine. RNA editing observed in humans with age are not Therefore, A-to-I RNA editing has important impli- observed during aging in healthy rats. Furthermore, we cations in altering specific amino acids, miRNA identify a conserved editing site in rats, in Cog3.We targeting, and in the modulation of alternative splicing propose that either age-related changes in RNA (Nishikura 2010). editing are specific to primates or humans, or that Targets of A-to-I RNA editing are often genes they are the manifestation of disease pathology.
    [Show full text]
  • Rabbit Anti-CYFIP2/FITC Conjugated Antibody-SL14140R-FITC
    SunLong Biotech Co.,LTD Tel: 0086-571- 56623320 Fax:0086-571- 56623318 E-mail:[email protected] www.sunlongbiotech.com Rabbit Anti-CYFIP2/FITC Conjugated antibody SL14140R-FITC Product Name: Anti-CYFIP2/FITC Chinese Name: FITC标记的细胞质FMR1相关蛋白2抗体 CYFP2; cytoplasmic FMR1 interacting protein 2; KIAA1168; p53 inducible protein; Alias: p53-inducible protein 121; PIR121; CYFP2_HUMAN. Organism Species: Rabbit Clonality: Polyclonal React Species: Human,Mouse,Rat,Chicken,Pig,Cow,Horse,Sheep, ICC=1:50-200IF=1:50-200 Applications: not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. Molecular weight: 146kDa Form: Lyophilized or Liquid Concentration: 1mg/ml immunogen: KLH conjugated synthetic peptide derived from human CYFIP2 Lsotype: IgG Purification: affinity purified by Protein A Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Storewww.sunlongbiotech.com at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year Storage: when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. background: CYFIP2 is a 1,278 amino acid protein encoded by the human gene CYFIP2. CYFIP2 belongs to the CYFIP family and is involved in T-cell adhesion and p53-dependent induction of apoptosis. It interacts with FMR1, FXR1 and FXR2 and is a component of Product Detail: the WAVE1 complex composed of Abi-2, CYFIP2, C3orf10/HSPC300, NAP125 and WASF1/WAVE1.
    [Show full text]
  • Collybistin Binds and Inhibits Mtorc1 Signaling: a Potential Novel Mechanism Contributing to Intellectual Disability and Autism
    European Journal of Human Genetics (2016) 24, 59–65 & 2016 Macmillan Publishers Limited All rights reserved 1018-4813/16 www.nature.com/ejhg ARTICLE Collybistin binds and inhibits mTORC1 signaling: a potential novel mechanism contributing to intellectual disability and autism Camila Oliveira Freitas Machado1, Karina Griesi-Oliveira1,2, Carla Rosenberg2, Fernando Kok2,3, Stephanie Martins1, Maria Rita Passos-Bueno2 and Andrea Laurato Sertie*,1 Protein synthesis regulation via mammalian target of rapamycin complex 1 (mTORC1) signaling pathway has key roles in neural development and function, and its dysregulation is involved in neurodevelopmental disorders associated with autism and intellectual disability. mTOR regulates assembly of the translation initiation machinery by interacting with the eukaryotic initiation factor eIF3 complex and by controlling phosphorylation of key translational regulators. Collybistin (CB), a neuron- specific Rho-GEF responsible for X-linked intellectual disability with epilepsy, also interacts with eIF3, and its binding partner gephyrin associates with mTOR. Therefore, we hypothesized that CB also binds mTOR and affects mTORC1 signaling activity in neuronal cells. Here, by using induced pluripotent stem cell-derived neural progenitor cells from a male patient with a deletion of entire CB gene and from control individuals, as well as a heterologous expression system, we describe that CB physically interacts with mTOR and inhibits mTORC1 signaling pathway and protein synthesis. These findings suggest that disinhibited
    [Show full text]
  • Cytoplasmic FMR1-Interacting Protein 2 Is a Major Genetic Factor Underlying Binge Eating
    Cytoplasmic FMR1-interacting protein 2 is a major genetic factor underlying binge eating Stacey L. Kirkpatrick1, Lisa R. Goldberg1,2, Neema Yazdani1,2,3, R. Keith Babbs1, Jiayi Wu1,3,4, Eric R. Reed1,5, David F. Jenkins5,6, Amanda Bolgioni1,2, Kelsey I. Landaverde1, Kimberly P. Luttik1, Karen S. Mitchell7, Vivek Kumar8, W. Evan Johnson6, Megan K. Mulligan9, Pietro Cottone10, Camron D. Bryant1* 1Laboratory of Addiction Genetics, Department of Pharmacology and Experimental Therapeutics and Department of Psychiatry, Boston University School of Medicine, Boston, MA USA 2Graduate Program in Biomolecular Pharmacology, Boston University School of Medicine, Boston, MA USA 3Transformative Training Program in Addiction Science, Boston University 4Ph.D. Program in Biomedical Sciences, Graduate Program in Genetics and Genomics, Boston University School of Medicine 5Ph.D. Program in Bioinformatics, Boston University, Boston, MA USA 6Computational Biomedicine, Boston University School of Medicine, Boston, MA USA 7Department of Psychiatry, Boston University School of Medicine, Boston, MA USA 8The Jackson Laboratory, Bar Harbor, ME USA 9Department of Anatomy and Neurobiology, University of Tennessee Health Science Center, Memphis, TN USA 10Laboratory of Addictive Disorders, Department of Pharmacology and Experimental Therapeutics and Department of Psychiatry, Boston University School of Medicine, Boston, MA USA Background: Eating disorders are lethal and heritable; however, the underlying genetic factors are unknown. Binge eating is a highly heritable trait associated with eating disorders that is comorbid with mood and substance use disorders. Therefore, understanding its genetic basis will inform therapeutic development that could improve several comorbid neuropsychiatric conditions. Methods: We assessed binge eating in closely related C57BL/6 mouse substrains and in an F2 cross to identify quantitative trait loci (QTL) associated with binge eating.
    [Show full text]